Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reg
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders
06:25pm, Saturday, 01'st Feb 2025
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
06:01pm, Saturday, 01'st Feb 2025
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between No
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:RE
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
06:15pm, Friday, 31'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
05:50pm, Friday, 31'st Jan 2025
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
02:25pm, Friday, 31'st Jan 2025
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.
